DARENasdaqPharmaceutical PreparationsUS GAAP · USD

Dare Bioscience, Inc.

Dare Bioscience, Inc. is a women’s health biopharmaceutical company developing and commercializing proprietary products across contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company is shifting from a pure development model toward a capital-efficient commercialization model that combines late-stage R&D with near-term revenue opportunities through Section 503B compounded products and consumer health offerings.

Kysy yhtiöstä
Liikevaihto1,0milj. USD
+10 429,4 %v/v
Liikevoitto (EBIT)−13,6milj. USD
+42,2 %v/v
EBIT-marginaali−1 315,5%
+238 376,7 %-yks.v/v
Nettotulos−13,4milj. USD
−230,6 %v/v
Vapaa kassavirta−10,3milj. USD
−309,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−40−30−20−10010milj. USD2020: EBIT −27 milj. USD20202021: 0,00 milj. USD2021: EBIT −39 milj. USD20212022: 10 milj. USD2022: EBIT −31 milj. USD20222023: 2,8 milj. USD2023: EBIT −31 milj. USD20232024: 0,01 milj. USD2024: EBIT −23 milj. USD20242025: 1,0 milj. USD2025: EBIT −14 milj. USD20251,0−14
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Commercialized and near-term commercial products20 %

Includes XACIATO and planned Section 503B/consumer health offerings such as DARE to PLAY Sildenafil Cream and DARE to RESTORE.

Late-stage women’s health product candidates35 %

Includes Ovaprene and DARE-HRT1, which are being advanced toward clinical and commercial milestones.

Early-stage clinical and preclinical programs25 %

Includes DARE-VVA1, DARE-HPV and other pipeline assets still in development.

Grant-funded development programs20 %

Programs supported by non-dilutive grants, including work tied to DARE-LARC1, Ovaprene and DARE-HPV.

Asiakkaat

Dare’s direct customers are healthcare providers, outsourcing facilities, telehealth partners, and third-party commercial partners that help bring its products to market. End users are women seeking solutions in contraception, sexual health, vaginal health, menopause, and related conditions, with some products intended for prescription use and others for consumer health channels.

Women’s health providers

Prescribe or recommend products such as Sildenafil Cream, XACIATO and future pipeline therapies because they address unmet women’s health needs.

Telehealth and consumer health partners

Help market and distribute non-prescription products like DARE to RESTORE and support direct-to-consumer awareness.

503B outsourcing facilities

Manufacture and dispense compounded products under the company’s Section 503B strategy.

Women patients and consumers

Buy or use the products for contraception, sexual health, vaginal health, menopause and related conditions.

Strategic collaborators and grant funders

Provide non-dilutive funding, development support, or commercialization access for specific programs.

Strategia

Dare is pursuing a capital-efficient transition from a development-stage biotech into a company with near-term commercial products and a broader women’s health portfolio. Its strategy is to use third-party manufacturing, strategic partnerships and targeted digital/provider marketing to avoid building a large internal sales force while still creating a commercial platform for future pipeline assets.

Launch near-term commercial productsLyhyt aikaväli

Creates initial revenue and market presence without building a full sales infrastructure.

Pursue capital-efficient commercializationLyhyt aikaväli

The company lacks internal sales and distribution capabilities, so partnerships reduce fixed costs and execution risk.

Advance late-stage women’s health pipelineKeskipitkä aikaväli

Clinical progress supports future FDA-approved products and longer-term value creation.

Reduce dependence on dilutive capitalKeskipitkä aikaväli

Management wants commercial and grant funding to help fund operations and reduce financing pressure.

Maantiede

The company is headquartered in the United States and its near-term commercial plans are centered on the U.S. market. It sources some vaginal probiotics from Europe for its consumer health strategy, but the core development, regulatory and commercialization work is U.S.-focused.

Riskit

The company remains highly dependent on external capital, clinical success and execution of a still-developing commercialization model. Its business also carries typical biotech risks around regulatory approval, product launch timing, manufacturing transfer, and the possibility that near-term revenue remains immaterial or delayed.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Insufficient capital to fund operations and development1Nasdaq listing compliance2Clinical development and regulatory approval risk3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Insufficient capital to fund operations and developmentVaikutus: KriittinenTodennäköisyys: Korkea

    The company states it may need to delay, scale back, or cease programs if it cannot raise funds on acceptable terms.

    KohdistuuR&DCommercializationCorporate operations
  2. Nasdaq listing complianceVaikutus: KorkeaTodennäköisyys: Korkea

    Failure to meet continued listing standards could impair liquidity and access to capital.

    Kohdistuu: Equity financing and market confidence

  3. Clinical development and regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea

    Pipeline value depends on successful IND filings, clinical studies and FDA outcomes.

    KohdistuuOvapreneDARE-HRT1DARE-VVA1DARE-HPV
  4. Commercial launch and adoption riskVaikutus: Korkea

    Near-term products may not generate meaningful revenue if provider adoption or consumer demand is weak.

    KohdistuuDARE to PLAY Sildenafil CreamDARE to RESTORE™DARE-HRT1
  5. Dependence on third partiesVaikutus: Keskitaso

    The company relies on outsourcing facilities, collaborators and marketing partners rather than owned infrastructure.

    KohdistuuManufacturingDistributionCommercialization

Kirjanpito

Harkinnanvaraiset erät
Grant accounting and deferred grant funding

Cash received under grants is restricted to specific project costs and can create deferred liabilities until spent.

Vaikutus: Affects cash, liabilities and the timing of R&D expense recognition

Going-concern assessment

Management explicitly notes dependence on future capital to continue operations.

Vaikutus: Can affect disclosure, valuation assumptions and investor risk perception

Milestone and in-license obligations

Commercial or development milestones may trigger payments to licensors or collaborators.

Vaikutus: Can create lumpy operating expenses or accrued liabilities

Stock-based compensation

Personnel costs include stock compensation in both R&D and G&A.

Vaikutus: Impacts reported operating loss and non-cash expense trends

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

Pure Bioscience, Inc.

PURE · Miscellaneous Chemical Products

Forte Biosciences, Inc.

Pharmaceutical Preparations

Harvard Bioscience, Inc

HBIO · Laboratory Analytical Instruments

Seres Therapeutics, Inc.

MCRB · Pharmaceutical Preparations

Vir Biotechnology, Inc.

VIR · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026